Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel
The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled i...
Gespeichert in:
| Veröffentlicht in: | Blood cancer discovery 2023-09, Vol.4 (5), p.365-373 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 373 |
|---|---|
| container_issue | 5 |
| container_start_page | 365 |
| container_title | Blood cancer discovery |
| container_volume | 4 |
| creator | Paiva, Bruno Manrique, Irene Rytlewski, Julie Campbell, Timothy Kazanecki, Christian C Martin, Nathan Anderson, Jr, Larry D Berdeja, Jesús G Lonial, Sagar Raje, Noopur S Lin, Yi Moreau, Philippe San-Miguel, Jesús F Munshi, Nikhil C Kaiser, Shari M |
| description | The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus |
| doi_str_mv | 10.1158/2643-3230.BCD-23-0044 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10472177</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2841880423</sourcerecordid><originalsourceid>FETCH-LOGICAL-c342t-30b95b0e80bd472371f21c975b1f7999bcb7a5fa7923110b1d3fdead3f1a4e9d3</originalsourceid><addsrcrecordid>eNpVkU1vFDEMhiNERavSnwDKkcuUJM40kxMquwUqFbUqpdcoH54laGayJDMg_j1ZdVnBJY5e269tPYS84uyc87Z7Ky4kNCCAnb9frRsBDWNSPiMne13q54c_sGNyVsp3xpgADgrgBTkGJbsLreQJ-fUQR2zWuMUp4DTTu5w2Uypz9PTRDgvS1NMvmNOQNtHbgdop0M9oy5KtG5DeY4lhqfo6lqoivSwFSxmrVaG2nzHT64DeutlucEL6GP2Ai8fhJTnq7VDwbB9PydcPVw-rT83N7cfr1eVN40GKuQHmdOsYdswFqQQo3gvutWod75XW2nmnbNtbpetxnDkeoA9o68utRB3glLx78t0ubsTg62LZDmab42jzb5NsNP9npvjNbNJPw1mdx5WqDm_2Djn9WLDMZoylXjDYCdNSjOgk7zomBdTS9qnU51RKxv4whzOzA2d2UMwOiqngjACzA1f7Xv-75KHrLyb4Azjslto</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2841880423</pqid></control><display><type>article</type><title>Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel</title><source>MEDLINE</source><source>PubMed Central</source><creator>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie ; Campbell, Timothy ; Kazanecki, Christian C ; Martin, Nathan ; Anderson, Jr, Larry D ; Berdeja, Jesús G ; Lonial, Sagar ; Raje, Noopur S ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús F ; Munshi, Nikhil C ; Kaiser, Shari M</creator><creatorcontrib>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie ; Campbell, Timothy ; Kazanecki, Christian C ; Martin, Nathan ; Anderson, Jr, Larry D ; Berdeja, Jesús G ; Lonial, Sagar ; Raje, Noopur S ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús F ; Munshi, Nikhil C ; Kaiser, Shari M</creatorcontrib><description>The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.
This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337.</description><identifier>ISSN: 2643-3230</identifier><identifier>ISSN: 2643-3249</identifier><identifier>EISSN: 2643-3249</identifier><identifier>DOI: 10.1158/2643-3230.BCD-23-0044</identifier><identifier>PMID: 37486974</identifier><language>eng</language><publisher>United States: American Association for Cancer Research</publisher><subject>Humans ; Immunotherapy, Adoptive ; Multiple Myeloma - therapy ; Neoplasm, Residual ; Neoplasms, Plasma Cell ; Prognosis ; Receptors, Chimeric Antigen - therapeutic use ; Research Brief</subject><ispartof>Blood cancer discovery, 2023-09, Vol.4 (5), p.365-373</ispartof><rights>2023 The Authors; Published by the American Association for Cancer Research.</rights><rights>2023 The Authors; Published by the American Association for Cancer Research 2023 American Association for Cancer Research</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c342t-30b95b0e80bd472371f21c975b1f7999bcb7a5fa7923110b1d3fdead3f1a4e9d3</citedby><cites>FETCH-LOGICAL-c342t-30b95b0e80bd472371f21c975b1f7999bcb7a5fa7923110b1d3fdead3f1a4e9d3</cites><orcidid>0000-0003-1780-8746 ; 0009-0002-6092-1891 ; 0000-0002-1556-6416 ; 0000-0003-1977-3815 ; 0000-0001-5244-6790 ; 0009-0002-2658-0958 ; 0000-0002-6531-9595 ; 0000-0002-7344-9795 ; 0000-0003-4362-0376 ; 0000-0003-3066-1275 ; 0000-0002-8322-9323 ; 0000-0002-9183-4857 ; 0009-0009-0020-6133 ; 0009-0003-8337-9123 ; 0000-0002-3538-8784</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472177/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10472177/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/37486974$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Manrique, Irene</creatorcontrib><creatorcontrib>Rytlewski, Julie</creatorcontrib><creatorcontrib>Campbell, Timothy</creatorcontrib><creatorcontrib>Kazanecki, Christian C</creatorcontrib><creatorcontrib>Martin, Nathan</creatorcontrib><creatorcontrib>Anderson, Jr, Larry D</creatorcontrib><creatorcontrib>Berdeja, Jesús G</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Raje, Noopur S</creatorcontrib><creatorcontrib>Lin, Yi</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>San-Miguel, Jesús F</creatorcontrib><creatorcontrib>Munshi, Nikhil C</creatorcontrib><creatorcontrib>Kaiser, Shari M</creatorcontrib><title>Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel</title><title>Blood cancer discovery</title><addtitle>Blood Cancer Discov</addtitle><description>The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.
This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337.</description><subject>Humans</subject><subject>Immunotherapy, Adoptive</subject><subject>Multiple Myeloma - therapy</subject><subject>Neoplasm, Residual</subject><subject>Neoplasms, Plasma Cell</subject><subject>Prognosis</subject><subject>Receptors, Chimeric Antigen - therapeutic use</subject><subject>Research Brief</subject><issn>2643-3230</issn><issn>2643-3249</issn><issn>2643-3249</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU1vFDEMhiNERavSnwDKkcuUJM40kxMquwUqFbUqpdcoH54laGayJDMg_j1ZdVnBJY5e269tPYS84uyc87Z7Ky4kNCCAnb9frRsBDWNSPiMne13q54c_sGNyVsp3xpgADgrgBTkGJbsLreQJ-fUQR2zWuMUp4DTTu5w2Uypz9PTRDgvS1NMvmNOQNtHbgdop0M9oy5KtG5DeY4lhqfo6lqoivSwFSxmrVaG2nzHT64DeutlucEL6GP2Ai8fhJTnq7VDwbB9PydcPVw-rT83N7cfr1eVN40GKuQHmdOsYdswFqQQo3gvutWod75XW2nmnbNtbpetxnDkeoA9o68utRB3glLx78t0ubsTg62LZDmab42jzb5NsNP9npvjNbNJPw1mdx5WqDm_2Djn9WLDMZoylXjDYCdNSjOgk7zomBdTS9qnU51RKxv4whzOzA2d2UMwOiqngjACzA1f7Xv-75KHrLyb4Azjslto</recordid><startdate>20230901</startdate><enddate>20230901</enddate><creator>Paiva, Bruno</creator><creator>Manrique, Irene</creator><creator>Rytlewski, Julie</creator><creator>Campbell, Timothy</creator><creator>Kazanecki, Christian C</creator><creator>Martin, Nathan</creator><creator>Anderson, Jr, Larry D</creator><creator>Berdeja, Jesús G</creator><creator>Lonial, Sagar</creator><creator>Raje, Noopur S</creator><creator>Lin, Yi</creator><creator>Moreau, Philippe</creator><creator>San-Miguel, Jesús F</creator><creator>Munshi, Nikhil C</creator><creator>Kaiser, Shari M</creator><general>American Association for Cancer Research</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1780-8746</orcidid><orcidid>https://orcid.org/0009-0002-6092-1891</orcidid><orcidid>https://orcid.org/0000-0002-1556-6416</orcidid><orcidid>https://orcid.org/0000-0003-1977-3815</orcidid><orcidid>https://orcid.org/0000-0001-5244-6790</orcidid><orcidid>https://orcid.org/0009-0002-2658-0958</orcidid><orcidid>https://orcid.org/0000-0002-6531-9595</orcidid><orcidid>https://orcid.org/0000-0002-7344-9795</orcidid><orcidid>https://orcid.org/0000-0003-4362-0376</orcidid><orcidid>https://orcid.org/0000-0003-3066-1275</orcidid><orcidid>https://orcid.org/0000-0002-8322-9323</orcidid><orcidid>https://orcid.org/0000-0002-9183-4857</orcidid><orcidid>https://orcid.org/0009-0009-0020-6133</orcidid><orcidid>https://orcid.org/0009-0003-8337-9123</orcidid><orcidid>https://orcid.org/0000-0002-3538-8784</orcidid></search><sort><creationdate>20230901</creationdate><title>Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel</title><author>Paiva, Bruno ; Manrique, Irene ; Rytlewski, Julie ; Campbell, Timothy ; Kazanecki, Christian C ; Martin, Nathan ; Anderson, Jr, Larry D ; Berdeja, Jesús G ; Lonial, Sagar ; Raje, Noopur S ; Lin, Yi ; Moreau, Philippe ; San-Miguel, Jesús F ; Munshi, Nikhil C ; Kaiser, Shari M</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c342t-30b95b0e80bd472371f21c975b1f7999bcb7a5fa7923110b1d3fdead3f1a4e9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Humans</topic><topic>Immunotherapy, Adoptive</topic><topic>Multiple Myeloma - therapy</topic><topic>Neoplasm, Residual</topic><topic>Neoplasms, Plasma Cell</topic><topic>Prognosis</topic><topic>Receptors, Chimeric Antigen - therapeutic use</topic><topic>Research Brief</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Paiva, Bruno</creatorcontrib><creatorcontrib>Manrique, Irene</creatorcontrib><creatorcontrib>Rytlewski, Julie</creatorcontrib><creatorcontrib>Campbell, Timothy</creatorcontrib><creatorcontrib>Kazanecki, Christian C</creatorcontrib><creatorcontrib>Martin, Nathan</creatorcontrib><creatorcontrib>Anderson, Jr, Larry D</creatorcontrib><creatorcontrib>Berdeja, Jesús G</creatorcontrib><creatorcontrib>Lonial, Sagar</creatorcontrib><creatorcontrib>Raje, Noopur S</creatorcontrib><creatorcontrib>Lin, Yi</creatorcontrib><creatorcontrib>Moreau, Philippe</creatorcontrib><creatorcontrib>San-Miguel, Jesús F</creatorcontrib><creatorcontrib>Munshi, Nikhil C</creatorcontrib><creatorcontrib>Kaiser, Shari M</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Blood cancer discovery</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Paiva, Bruno</au><au>Manrique, Irene</au><au>Rytlewski, Julie</au><au>Campbell, Timothy</au><au>Kazanecki, Christian C</au><au>Martin, Nathan</au><au>Anderson, Jr, Larry D</au><au>Berdeja, Jesús G</au><au>Lonial, Sagar</au><au>Raje, Noopur S</au><au>Lin, Yi</au><au>Moreau, Philippe</au><au>San-Miguel, Jesús F</au><au>Munshi, Nikhil C</au><au>Kaiser, Shari M</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel</atitle><jtitle>Blood cancer discovery</jtitle><addtitle>Blood Cancer Discov</addtitle><date>2023-09-01</date><risdate>2023</risdate><volume>4</volume><issue>5</issue><spage>365</spage><epage>373</epage><pages>365-373</pages><issn>2643-3230</issn><issn>2643-3249</issn><eissn>2643-3249</eissn><abstract>The role of measurable residual disease (MRD) in multiple myeloma patients treated with chimeric antigen receptor (CAR) T cells is uncertain. We analyzed MRD kinetics during the first year after idecabtagene vicleucel (ide-cel) infusion in 125 relapsed/refractory multiple myeloma patients enrolled in KarMMa. At month 1 after ide-cel, there were no differences in progression-free survival (PFS) between patients in less than complete response (CR) versus those in CR; only MRD status was predictive of significantly different PFS at this landmark. In patients with undetectable MRD at 3 months and beyond, PFS was longer in those achieving CR versus <CR. Persistent MRD in the 10-6 logarithmic range and reappearance of normal plasma cells in MRD-negative patients were associated with inferior PFS. This study unveils different prognostic implications of serological and MRD response dynamics after ide-cel and suggests the potential value of studying the reappearance of normal plasma cells as a surrogate of loss of CAR T-cell functionality.
This is one of the first studies evaluating the impact of CR and MRD dynamics after CAR T therapy in relapsed/refractory multiple myeloma. These data help interpret the prognostic significance of serological and MRD responses at early and late time points after CAR T-cell infusion. See related commentary by Landgren and Kazandjian, p. 346 . This article is featured in Selected Articles from This Issue, p. 337.</abstract><cop>United States</cop><pub>American Association for Cancer Research</pub><pmid>37486974</pmid><doi>10.1158/2643-3230.BCD-23-0044</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0003-1780-8746</orcidid><orcidid>https://orcid.org/0009-0002-6092-1891</orcidid><orcidid>https://orcid.org/0000-0002-1556-6416</orcidid><orcidid>https://orcid.org/0000-0003-1977-3815</orcidid><orcidid>https://orcid.org/0000-0001-5244-6790</orcidid><orcidid>https://orcid.org/0009-0002-2658-0958</orcidid><orcidid>https://orcid.org/0000-0002-6531-9595</orcidid><orcidid>https://orcid.org/0000-0002-7344-9795</orcidid><orcidid>https://orcid.org/0000-0003-4362-0376</orcidid><orcidid>https://orcid.org/0000-0003-3066-1275</orcidid><orcidid>https://orcid.org/0000-0002-8322-9323</orcidid><orcidid>https://orcid.org/0000-0002-9183-4857</orcidid><orcidid>https://orcid.org/0009-0009-0020-6133</orcidid><orcidid>https://orcid.org/0009-0003-8337-9123</orcidid><orcidid>https://orcid.org/0000-0002-3538-8784</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2643-3230 |
| ispartof | Blood cancer discovery, 2023-09, Vol.4 (5), p.365-373 |
| issn | 2643-3230 2643-3249 2643-3249 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10472177 |
| source | MEDLINE; PubMed Central |
| subjects | Humans Immunotherapy, Adoptive Multiple Myeloma - therapy Neoplasm, Residual Neoplasms, Plasma Cell Prognosis Receptors, Chimeric Antigen - therapeutic use Research Brief |
| title | Time-Dependent Prognostic Value of Serological and Measurable Residual Disease Assessments after Idecabtagene Vicleucel |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T22%3A46%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Time-Dependent%20Prognostic%20Value%20of%20Serological%20and%20Measurable%20Residual%20Disease%20Assessments%20after%20Idecabtagene%20Vicleucel&rft.jtitle=Blood%20cancer%20discovery&rft.au=Paiva,%20Bruno&rft.date=2023-09-01&rft.volume=4&rft.issue=5&rft.spage=365&rft.epage=373&rft.pages=365-373&rft.issn=2643-3230&rft.eissn=2643-3249&rft_id=info:doi/10.1158/2643-3230.BCD-23-0044&rft_dat=%3Cproquest_pubme%3E2841880423%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2841880423&rft_id=info:pmid/37486974&rfr_iscdi=true |